

**Freedom of Information Request**

**Ref: 23-700**

11 October 2023

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we hold some of the information you are requesting

**I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of Jun 2023 to the end of Aug 2023, or the latest three-month period for which data is available. Please include data for all hospitals in the Trust.**

**Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of June 2023 and end of August 2023? Please provide data for the latest 3-month period, if Jun to Aug is not available yet**

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	87
1.2 Alpelisib (Piqray)	*
1.3 Fulvestrant (fulvestrant or Faslodex)	47
1.4 Palbociclib (Ibrance)	107
1.5 Ribociclib (Kisqali)	0

Please note: Where the figures are between 1 and 5, this has been denoted by \*. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts,

providers and Trusts may allow identification of patients and should not be published.

**Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of June 2023 and end of August 2023?**

**Please provide data for the latest 3-month period, if Jun to Aug is not available yet**

Number patients treated

We cannot provide this information as the Trust's e-prescribing system does not record staging in this way

**Q3. How many patients received abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the 3 months between the start of June 2023 and end of August 2023?**

**Please provide data for the latest 3-month period, if Jun to Aug is not available yet**

We cannot provide this information as the Trust's e-prescribing system does not record staging in this way

Number patients treated

We cannot provide this information as the Trust's e-prescribing system does not record staging in this way

**Q4. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of June 2023 and end of August 2023?**

**Please provide data for the latest 3-month period, if Jun to Aug is not available yet**

Treatment intent	Number patients treated
4.1 Curative	36
4.2 Palliative	37
4.3 Not known / stated	*

Please note: Where the figures are between 1 and 5, this has been denoted by \*. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. This follows NHS Digital (formerly HSCIC) analysis guidance

(2014) which states that small numbers within local authorities, wards, postcode districts, providers and Trusts may allow identification of patients and should not be published.

**Q5. How many patients were treated with the following medicines in combination in the 3 months between the start of June 2023 and end of August 2023?**

**Please provide data for the latest 3-month period, if Jun to Aug is not available yet**

Name of combination or monotherapy	Number patients treated
5.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	15
5.2 Abemaciclib (Verzenios) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	49
5.3 Abemaciclib (Verzenois) + tamoxifen	0
5.4 Abemaciclib monotherapy	0
5.5 Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)	*
5.6 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	23
5.7 Palbociclib (Ibrance) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	78
5.8 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	0
5.9 Ribociclib (Kisqali) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	0

Please note: Where the figures are between 1 and 5, this has been denoted by \*. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, providers and Trusts may allow identification of patients and should not be published.

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Data Protection Officer  
University Hospitals Bristol and Weston NHS Foundation Trust  
Trust Headquarters  
Marlborough Street  
Bristol  
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

#### Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

**Freedom of Information Team**  
**University Hospitals Bristol and Weston NHS Foundation Trust**